WO1999021857A1 - 3-substituierte tetrahydropyridopyrimidinon-derivate, ihre herstellung und verwendung - Google Patents
3-substituierte tetrahydropyridopyrimidinon-derivate, ihre herstellung und verwendung Download PDFInfo
- Publication number
- WO1999021857A1 WO1999021857A1 PCT/EP1998/006305 EP9806305W WO9921857A1 WO 1999021857 A1 WO1999021857 A1 WO 1999021857A1 EP 9806305 W EP9806305 W EP 9806305W WO 9921857 A1 WO9921857 A1 WO 9921857A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- substituted
- branched
- unbranched
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the invention relates to 3-substituted tetrahydropyridopyrimidine non-derivatives, their preparation and use for the preparation of pharmaceutical active ingredients.
- SSRls selective serotonin reuptake inhibitors
- presynaptic serotonin autoreceptors increases the release of the negative coupling, the serotonin release and thus the current transmitter concentration in the synaptic cleft. This increase in transmitter concentration is considered the antidepressant principle.
- This mechanism of action differs from the previously known antidepressants, which simultaneously activate the presynaptic and somatodendritic autoreceptors and therefore lead to a delayed onset of action only after desensitization of these autoreceptors.
- the direct auto-receptor blockade circumvents this effect.
- JP 08027149 and JP 04054181 are known.
- the presynaptic serotonin autoreceptor is of the 5-HT_ B subtype (Fink et al., Arch. Pharmacol. 352 (1995), p 451). Its selective blockage by 5-HT_B / D antagonists increases the release of serotonin in the brain: GW Price et al. , Behavioral Brain Research 73 (1996), pp. 79-82; PH Hutson et al. , Neuropharmacology Vol. 34, No. 4 (1995), pp. 383-392.
- the selective 5-HT IB antagonist GR 127 935 surprisingly reduces the serotonin release in the cortex after systemic administration.
- One explanation could be the stimulation of somatode-third-party 5-HT_ A receptors in the Raphe region by the released serotonin, which increases the rate of fire of serotonergic neurons and thus inhibits the release of serotonin (M. Skingle et al., Neuropharmacology Vol. 34 No. 4 (1995), pp. 377-382, pp. 393-402).
- the second strategy includes blockade of both types of autoreceptors with one, namely the 5-HT_ A receptors, to enhance neuronal firing, and the 5-HT_ B receptors to the terminal serotonin release to raise (Starkey and Skingle, Neuropharmacology 11 (3-4) (1994), 393).
- 5-HTi ß / D antagonists alone or coupled with a 5-HT ⁇ A receptor antagonistic component should therefore increase the release of serotonin in the brain and could therefore include advantages in the therapy of depression and related mental illnesses.
- one of the two radicals X, Y represents CH and the other represents NR 1 ,
- R 1 for hydrogen, (C__ 6 ) alkyl branched or unbranched, CO- (C ⁇ _ 4 ) alkyl, C0 2 tBu, CO-aryl and a phenylalkyl- C_-C 4 radical, which in turn on the aromatic through F, Cl, Br, I, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, trifluoromethyl, hydroxy, amino, cyano or nitro can be substituted,
- A represents branched or unbranched (C ⁇ _ u .) Alkylene or straight-chain or branched (C 2 -ioe) alkylene which comprises at least one group Z which is selected from 0, S, NR 2 , cyclopropyl, CHOH, a double or triple bond, R 2 represents hydrogen and C 1 -C 4 alkyl,
- B represents 4-piperidine, 4-tetrahydro-l, 2, 3, 6 pyridine, 4-piperazine and the corresponding ring compounds enlarged by a methylene group, the linkage to A taking place via an N atom of B and
- Ar for phenyl which is branched or unbranched by (C ⁇ - 6 ) alkyl, 0- (C ⁇ _ 6 ) alkyl branched or unbranched, OH, F, Cl, Br, I, trifluoromethyl, NR 2 2 , C0 2 R J , Cyano or
- Phenyl is substituted, tetralin, indane, more highly condensed aromatics such as naphthalene, which is optionally substituted by (C : -) alkyl or 0 (C; - 4 ) alkyl, anthracene or 5- or 6-membered aromatic heterocycles with 1 to 2 Heteroatoms which are selected independently of one another under O and N and which may also be fused with further aromatic radicals,
- one of the two radicals X, Y represents CH 2 and the other represents NR 1 ,
- R 1 for hydrogen, (C 1 -. 4 ) alkyl branched or unbranched, CO- (C 1 - 4 ) alkyl, C0tBu, COPh or a phenylalkyl C_-C 2 radical, which in turn on the aromatic through F, Cl , Br, I, C 1 -C 4 alkyl, -C-C 4 alkoxy, trifluoromethyl, hydroxy or cyano may be substituted,
- (C 2 - 5) alkylene group which comprises a group Z which is selected from CHOH, cyclopropyl, a double or a triple bond,
- B represents 4-piperidine, 4-tetrahydro-1, 2, 3, 6 pyridine, 4-piperazine or homopiperazine, the linkage to A being via an N atom of B and
- Ar for phenyl which is optionally branched or unbranched by (C__ 6 ) alkyl, 0- (C__ 6 ) alkyl branched or unbranched, F, Cl, Br, I, trifluoromethyl, C0 2 R 2 , NR 2 2 , cyano or phenyl, tetralin, indan, highly condensed aromatics such as naphthalene, which is optionally substituted by (C 1 - 4) alkyl or
- C__ 4 alkyl is substituted or 5- or 6-membered aromatic table heterocycles with 1 to 2 nitrogen, which can be fused with other aromatic residues.
- Particularly preferred compounds of formula I are the compounds listed in claim 3.
- the compounds of formula I can have one or more centers of asymmetry.
- the invention therefore includes not only the racemates, but also the enantiomers and diastereomers concerned.
- the respective tautomeric forms also belong to the invention.
- A, X and Y have the meaning given above and Q represents a cleavable group (for example Cl, Br, I, alkanesulfonyloxy or arylsulfonyloxy), with a compound of the formula III,
- Another synthesis variant is the linking of a compound of the formula VI with a compound of formula III by a known reductive amination.
- B 1 is piperazine or homopiperazine and W is hydrogen or one of the usual amino protecting groups (such as Boc or Cbz), with a compound of general formula VIII
- P is B (OH) 2 , SnR 3 , OTf, Br, Cl, or I and R is Ci-C ⁇ -alkyl, in a known manner; or
- B 3 stands for piperidines linked in the 1,4-position and the corresponding ring compounds enlarged by a methylene group
- the reactions described above are generally carried out in an inert organic solvent, e.g. B. dimethylformamide, acetonitrile, dichloromethane, dimethyl sulfoxide, dirthhoxyethane, toluene, ethyl acetate, xylene, a ketone, e.g. Acetone or
- methyl ethyl ketone an alcohol such as ethanol or n-butanol, or a cyclic saturated ether, e.g. Tetrahydrofuran or dioxane.
- the reactions are usually carried out at temperatures between 45 20 ° C and the boiling point of the solvent and are generally completed within 1 to 20 hours. If desired, one works in the presence of an acid-binding agent such as Sodium or potassium carbonate, sodium methylate, sodium ethylate, sodium hydride, organometallic compounds (butyllithium, alkyl magnesium compounds), potassium t-butoxide, pyridine or triethylamine.
- an acid-binding agent such as Sodium or potassium carbonate, sodium methylate, sodium ethylate, sodium hydride, organometallic compounds (butyllithium, alkyl magnesium compounds), potassium t-butoxide, pyridine or triethylamine.
- the reactions are optionally carried out using a catalyst, such as. B. transition metals and their complexes, for example Pd-C, Pd (PPh 3 ) 4 , Pd (OAc) 2 , Pd (P (oTol) 3 ) 4, Pd 2 (dba) 3 or Ni (COD) 2 .
- a catalyst such as. B. transition metals and their complexes, for example Pd-C, Pd (PPh 3 ) 4 , Pd (OAc) 2 , Pd (P (oTol) 3 ) 4, Pd 2 (dba) 3 or Ni (COD) 2 .
- the crude product is isolated in the customary manner, for example by filtration, distilling off the solvent or extraction from the reaction mixture.
- the compounds of the formula I according to the invention can be purified either by recrystallization from the customary organic solvents or by column chromatography.
- the invention also includes the acid addition salts of the compounds of the formula I with physiologically tolerated acids.
- suitable physiologically acceptable organic and inorganic acids are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, adipic acid or benzoic acid. Further useful acids are described in "Progress in Drug Research", Volume 10, pages 224 ff., Birk Reifen Verlag, Basel and Stuttgart, 1966.
- the acid addition salts are in a conventional manner by mixing the free base with the corresponding acid, optionally in solution in an organic solvent, for example a lower alcohol, such as methanol, ethanol or propanol, an ether, such as methyl t-butyl ether, a ketone, such as Acetone or methyl ethyl ketone or an ester such as ethyl acetate.
- an organic solvent for example a lower alcohol, such as methanol, ethanol or propanol, an ether, such as methyl t-butyl ether, a ketone, such as Acetone or methyl ethyl ketone or an ester such as ethyl acetate.
- the invention also relates to a therapeutic agent, characterized in that it contains a compound of the formula I or its pharmacologically acceptable acid addition salt as active ingredient in addition to conventional carriers and diluents, and the use of the new compounds in combating diseases.
- the compounds according to the invention can be administered in the usual way orally or parenterally, intravenously or intramuscularly.
- the dosage depends on the age, condition and weight of the patient and on the type of application.
- the daily dose of active substance is between approximately 1 and 100 mg / kg body weight when administered orally and between 0.1 and 10 mg / kg body weight when administered parenterally.
- the new compounds can be used in common galenical application forms, solid or liquid, e.g. as tablets, film-coated tablets, capsules, powders, granules, dragees, suppositories, solutions, ointments, creams or sprays. These are manufactured in the usual way.
- the active ingredients can be processed with the usual pharmaceutical auxiliaries such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardants, antioxidants and / or propellants (see H. Sucker et. Al: Pharmaceuticals Technology, Thieme-Verlag, Stuttgart, 1978).
- the administration forms obtained in this way normally contain the active ingredient in an amount of 1 to 99% by weight.
- the compounds of the invention have a high affinity for the serotonin receptors 5-HT ⁇ B , 5-HT iD and 5-HT ⁇ A.
- the affinity for these receptors is approximately the same, at least of the same order of magnitude.
- some of the compounds according to the invention have good serotonin reuptake inhibition - a principle which is implemented in most antidepressants.
- These compounds are useful as pharmaceuticals for the treatment of disease states in which the serotonin concentration is reduced and in which one would like as part of a therapy specifically block the activity of the presynaptic receptors 5-HT ⁇ B, 5-HT 1A, 5-HT ⁇ D without to strongly influence other receptors. Depression is one such condition.
- the compounds of the present invention can also be useful in the treatment of central nervous disorders such as seasonal mood disorders and dysthymia. This also includes anxiety such as generalized anxiety, panic attacks, sociophobia, obsessive-compulsive disorders and post-traumatic stress symptoms, memory disorders including dementia, amnesias and age-related memory loss as well as psychogenic eating disorders such as anorexia nervosa and bulimia nervosa.
- the compounds according to the invention can also be useful for the treatment of endocrine diseases such as hyperprolactinemia and for the treatment of vascular spasms (in particular the brain vessels), hypertension and gastrointestinal disorders which are associated with motility and secretion disorders. Another area of application is sexual disorders.
- the hydrochloride was converted from the solution of the residue in ethyl acetate by adding 30% isopropanol / HCl solution like, which was dried after vacuuming at 40 ° C in a vacuum drying cabinet. 17 g (67%) of substance were obtained. Mp: 200 ° C.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Structure And Mechanism Of Cameras (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020007004362A KR20010015787A (ko) | 1997-10-24 | 1998-10-05 | 테트라히드로피리도피리미디논의 제3 위치 치환 유도체,그의 제조 방법 및 용도 |
IDW20000762D ID24633A (id) | 1997-10-24 | 1998-10-05 | Turunan tetrahidropirimidinon 3-tersubstitusi, pembuatan dan penggunaannya |
DK98951491T DK1025100T3 (da) | 1997-10-24 | 1998-10-05 | 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf |
SK387-2000A SK3872000A3 (en) | 1997-10-24 | 1998-10-05 | 3-SUBSTITUTED TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVES, METHODì (54) FOR PRODUCING THE SAME, AND THEIR USE |
PL98340034A PL340034A1 (en) | 1997-10-24 | 1998-10-05 | Derivatives of tetrahydropyridopyrimidinone substituted at position 3, method of obtaining them and method of applying them |
NZ503486A NZ503486A (en) | 1997-10-24 | 1998-10-05 | Serotonin antagonists 3-substituted tetrahydropyridopyrimidinone derivatives for treating 5HT, depression and related disorders |
AU97484/98A AU748666B2 (en) | 1997-10-24 | 1998-10-05 | 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use |
BR9812970-8A BR9812970A (pt) | 1997-10-24 | 1998-10-05 | Derivado de tetraidropiridopirimidinona 3-substituìda, e, uso deste |
DE59802922T DE59802922D1 (de) | 1997-10-24 | 1998-10-05 | 3-substituierte tetrahydropyridopyrimidinon-derivate, ihre herstellung und verwendung |
CA002305258A CA2305258A1 (en) | 1997-10-24 | 1998-10-05 | 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use |
JP2000517967A JP2001521035A (ja) | 1997-10-24 | 1998-10-05 | 3−置換テトラヒドロピリドピリミジノン−誘導体、その製造方法及びその使用 |
HU0004648A HUP0004648A3 (en) | 1997-10-24 | 1998-10-05 | 3-substituted tetrahydropyridopyrimidinone derivatives and their use for producing pharmaceutical compositions |
AT98951491T ATE212346T1 (de) | 1997-10-24 | 1998-10-05 | 3-substituierte tetrahydropyridopyrimidinon- derivate, ihre herstellung und verwendung |
EP98951491A EP1025100B1 (de) | 1997-10-24 | 1998-10-05 | 3-substituierte tetrahydropyridopyrimidinon-derivate, ihre herstellung und verwendung |
SI9830101T SI1025100T1 (en) | 1997-10-24 | 1998-10-05 | 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use |
BG104291A BG104291A (en) | 1997-10-24 | 2000-04-03 | 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use |
NO20001934A NO20001934L (no) | 1997-10-24 | 2000-04-13 | 3-Substituerte tetrahydropyridopyrimidinon-derivater, deres fremstilling og anvendelse |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19747063A DE19747063A1 (de) | 1997-10-24 | 1997-10-24 | 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung |
DE19747063.7 | 1997-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999021857A1 true WO1999021857A1 (de) | 1999-05-06 |
Family
ID=7846539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/006305 WO1999021857A1 (de) | 1997-10-24 | 1998-10-05 | 3-substituierte tetrahydropyridopyrimidinon-derivate, ihre herstellung und verwendung |
Country Status (27)
Country | Link |
---|---|
US (1) | US6414157B1 (de) |
EP (1) | EP1025100B1 (de) |
JP (1) | JP2001521035A (de) |
KR (1) | KR20010015787A (de) |
CN (1) | CN1277611A (de) |
AR (1) | AR015466A1 (de) |
AT (1) | ATE212346T1 (de) |
AU (1) | AU748666B2 (de) |
BG (1) | BG104291A (de) |
BR (1) | BR9812970A (de) |
CA (1) | CA2305258A1 (de) |
CO (1) | CO4980862A1 (de) |
DE (2) | DE19747063A1 (de) |
DK (1) | DK1025100T3 (de) |
ES (1) | ES2172222T3 (de) |
HR (1) | HRP980554A2 (de) |
HU (1) | HUP0004648A3 (de) |
ID (1) | ID24633A (de) |
NO (1) | NO20001934L (de) |
NZ (1) | NZ503486A (de) |
PL (1) | PL340034A1 (de) |
PT (1) | PT1025100E (de) |
SK (1) | SK3872000A3 (de) |
TR (1) | TR200001102T2 (de) |
TW (1) | TW432063B (de) |
WO (1) | WO1999021857A1 (de) |
ZA (1) | ZA989664B (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000041697A1 (de) * | 1999-01-11 | 2000-07-20 | Basf Aktiengesellschaft | Verwendung von 2-substituierten 1,2-benzisothiazol-derivaten und von 3-substituierten tetrahydropyridopyrimidinon-derivaten zur prophylaxe und therapie der zerebralen ischämie |
WO2005105759A1 (de) * | 2004-04-28 | 2005-11-10 | Grünenthal GmbH | SUBSTITUIERTE 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-d]PYRIMIDIN-2-YL- UND 5, 6, 7, 8-TETRAHYDRO-CHINAZOLIN-2-YL-VERBINDUNGEN |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014909A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
US20040127501A1 (en) * | 2002-09-24 | 2004-07-01 | Zhengming Chen | Therapeutic agents useful for treating pain |
JP4654035B2 (ja) | 2002-11-05 | 2011-03-16 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗菌剤 |
CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
US20050165025A1 (en) * | 2004-01-22 | 2005-07-28 | Recordati Ireland Ltd. | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists |
MX2007012083A (es) * | 2005-04-01 | 2007-11-20 | Warner Lambert Co | Tetrahidro-piridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia. |
CN101296914B (zh) * | 2005-08-26 | 2012-07-18 | 盐野义制药株式会社 | 具有ppar激动活性的衍生物 |
CN102952129B (zh) * | 2011-08-16 | 2015-09-23 | 上海师范大学 | 四氢吡啶并二氢嘧啶酮衍生物及其制备方法和应用 |
WO2022087011A1 (en) | 2020-10-21 | 2022-04-28 | Aligos Therapeutics, Inc. | Bicyclic compounds |
US11957683B2 (en) | 2021-06-18 | 2024-04-16 | Aligos Therapeutics, Inc. | Bicyclic compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0827149A (ja) * | 1994-07-08 | 1996-01-30 | Meiji Seika Kaisha Ltd | ピリミジノン誘導体およびその塩 |
-
1997
- 1997-10-24 DE DE19747063A patent/DE19747063A1/de not_active Withdrawn
-
1998
- 1998-10-05 AT AT98951491T patent/ATE212346T1/de not_active IP Right Cessation
- 1998-10-05 ES ES98951491T patent/ES2172222T3/es not_active Expired - Lifetime
- 1998-10-05 DK DK98951491T patent/DK1025100T3/da active
- 1998-10-05 KR KR1020007004362A patent/KR20010015787A/ko not_active Application Discontinuation
- 1998-10-05 ID IDW20000762D patent/ID24633A/id unknown
- 1998-10-05 SK SK387-2000A patent/SK3872000A3/sk unknown
- 1998-10-05 TR TR2000/01102T patent/TR200001102T2/xx unknown
- 1998-10-05 DE DE59802922T patent/DE59802922D1/de not_active Expired - Fee Related
- 1998-10-05 NZ NZ503486A patent/NZ503486A/en unknown
- 1998-10-05 CN CN98810525A patent/CN1277611A/zh active Pending
- 1998-10-05 BR BR9812970-8A patent/BR9812970A/pt not_active IP Right Cessation
- 1998-10-05 HU HU0004648A patent/HUP0004648A3/hu unknown
- 1998-10-05 JP JP2000517967A patent/JP2001521035A/ja active Pending
- 1998-10-05 AU AU97484/98A patent/AU748666B2/en not_active Ceased
- 1998-10-05 CA CA002305258A patent/CA2305258A1/en not_active Abandoned
- 1998-10-05 WO PCT/EP1998/006305 patent/WO1999021857A1/de not_active Application Discontinuation
- 1998-10-05 PL PL98340034A patent/PL340034A1/xx unknown
- 1998-10-05 EP EP98951491A patent/EP1025100B1/de not_active Expired - Lifetime
- 1998-10-05 PT PT98951491T patent/PT1025100E/pt unknown
- 1998-10-20 TW TW087117332A patent/TW432063B/zh not_active IP Right Cessation
- 1998-10-21 HR HR19747063.7A patent/HRP980554A2/hr not_active Application Discontinuation
- 1998-10-22 CO CO98061508A patent/CO4980862A1/es unknown
- 1998-10-23 AR ARP980105297A patent/AR015466A1/es not_active Application Discontinuation
- 1998-10-23 ZA ZA9809664A patent/ZA989664B/xx unknown
-
2000
- 2000-04-03 BG BG104291A patent/BG104291A/xx unknown
- 2000-04-10 US US09/529,231 patent/US6414157B1/en not_active Expired - Lifetime
- 2000-04-13 NO NO20001934A patent/NO20001934L/no not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
F. CLAUDI ET AL.: "3-[2-(4-Fluorobenzoyl)piperidin-1-yl]ethyl]-5,6,7,8-tetrahydro-4(3H)-quinazolinones: serotonin 5-HT2A receptor antagonists endowed with potent central action", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.CHIMICA THERAPEUTICA., vol. 32, no. 7-8, 1997, PARIS FR, pages 651 - 658, XP002095654 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000041697A1 (de) * | 1999-01-11 | 2000-07-20 | Basf Aktiengesellschaft | Verwendung von 2-substituierten 1,2-benzisothiazol-derivaten und von 3-substituierten tetrahydropyridopyrimidinon-derivaten zur prophylaxe und therapie der zerebralen ischämie |
WO2005105759A1 (de) * | 2004-04-28 | 2005-11-10 | Grünenthal GmbH | SUBSTITUIERTE 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-d]PYRIMIDIN-2-YL- UND 5, 6, 7, 8-TETRAHYDRO-CHINAZOLIN-2-YL-VERBINDUNGEN |
US7662828B2 (en) | 2004-04-28 | 2010-02-16 | Gruenenthal Gmbh | Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds |
Also Published As
Publication number | Publication date |
---|---|
HUP0004648A3 (en) | 2001-11-28 |
SK3872000A3 (en) | 2000-09-12 |
JP2001521035A (ja) | 2001-11-06 |
US6414157B1 (en) | 2002-07-02 |
DK1025100T3 (da) | 2002-05-06 |
EP1025100A1 (de) | 2000-08-09 |
BR9812970A (pt) | 2000-08-08 |
NO20001934D0 (no) | 2000-04-13 |
CN1277611A (zh) | 2000-12-20 |
AU748666B2 (en) | 2002-06-06 |
ATE212346T1 (de) | 2002-02-15 |
PT1025100E (pt) | 2002-07-31 |
PL340034A1 (en) | 2001-01-15 |
HRP980554A2 (en) | 1999-08-31 |
NO20001934L (no) | 2000-04-13 |
DE59802922D1 (de) | 2002-03-14 |
ID24633A (id) | 2000-07-27 |
CO4980862A1 (es) | 2000-11-27 |
TW432063B (en) | 2001-05-01 |
BG104291A (en) | 2001-05-31 |
TR200001102T2 (tr) | 2000-08-21 |
AR015466A1 (es) | 2001-05-02 |
CA2305258A1 (en) | 1999-05-06 |
ZA989664B (en) | 2000-04-25 |
KR20010015787A (ko) | 2001-02-26 |
HUP0004648A2 (hu) | 2001-05-28 |
DE19747063A1 (de) | 1999-04-29 |
ES2172222T3 (es) | 2002-09-16 |
NZ503486A (en) | 2001-04-27 |
EP1025100B1 (de) | 2002-01-23 |
AU9748498A (en) | 1999-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1497279B1 (de) | Substituierte indole und deren verwendung als 5ht-wiederaufnahme inhibitoren und als 5ht liganden | |
DE60315516T2 (de) | Pyridazinon-derivate als cdk2-hemmer | |
EP0988306B1 (de) | 3-substituierte 3,4-dihydro-thieno 2,3-d]pyrimidin-derivate, ihre herstellung und verwendung | |
DE60305484T2 (de) | Verbindungen und deren verwendung als 5-ht inhibitoren | |
EP1025100B1 (de) | 3-substituierte tetrahydropyridopyrimidinon-derivate, ihre herstellung und verwendung | |
DE19636769A1 (de) | 3-Substituierte Pyrido [4',3':4,5]thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung | |
EP1034170A1 (de) | 2-substituierte 1,2-benzisothiazol-derivate und ihre verwendung als serotonin-antagonisten (5-ht1a, 5-ht1b und 5-ht1d) | |
EP1003752A1 (de) | 3-substituierte 3,4,5,7-tetrahydro-pyrrolo 3',4':4,5] thieno 2,3-d] pyrimidin-derivate, ihre herstellung und verwendung als 5ht-antagonisten | |
WO2003059892A1 (de) | Substituierte alkyluracile und ihre verwendung | |
WO1983004254A1 (en) | Piperazine derivative compounds, production method thereof and drugs containing them | |
DE3900028A1 (de) | Gegebenenfalls am phenylrest halogen- und/oder alkyl- und/oder alkoxy- oder methylendioxysubstituierte, 5,5-di-(methyl)-3-(phenylvinyl)-1-(substituiert amino-alkoxy-imino)-cyclohex-2-enderivate, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel | |
EP1140099A1 (de) | Verwendung von 2-substituierten 1,2-benzisothiazol-derivaten und von 3-substituierten tetrahydropyridopyrimidinon-derivaten zur prophylaxe und therapie der zerebralen ischämie | |
EP1023296B1 (de) | 3-SUBSTITUIERTE PYRIDO 3',4':4,5] THIENO 2,3-d] PYRIMIDIN-DERIVATE, IHRE HERSTELLUNG UND VERWENDUNG | |
EP0580644B1 (de) | 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung | |
EP0696289B1 (de) | Benzo[f]chinoxalindionderivative, deren herstellung und verwendung in arzneimitteln | |
MXPA00002601A (en) | 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use | |
CZ20001436A3 (cs) | Disubstituované deriváty 1,2-benzisotiazolu a jejich použití | |
MXPA00003136A (en) | 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-ht1a, 5-ht1b and 5-ht1d) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 135084 Country of ref document: IL Ref document number: 98810525.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BG BR BY CA CN CZ GE HR HU ID IL JP KR KZ LT LV MK MX NO NZ PL RO RU SG SI SK TR UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/002601 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3872000 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 503486 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998951491 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2305258 Country of ref document: CA Ref document number: 2305258 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09529231 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-1454 Country of ref document: CZ Ref document number: 97484/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000/01102 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007004362 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1998951491 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-1454 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007004362 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998951491 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 97484/98 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007004362 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2000-1454 Country of ref document: CZ |